Anticonvulsant activity of PNU-151774E in the amygdala kindled model of complex partial seizures

Epilepsia

Volumn 40, Issue 11, 1999, Pages 1523-1528

  Maj, Roberto ^b   Fariello, Ruggero G ^c   Pevarello, Paolo ^a   Varasi, Mario ^a   McArthur, Robert A ^a   Salvati, Patricia ^c  

^a Pharmacia and Upjohn   (Italy)

^b Newron Pharmaceuticals   (Italy)

^c NONE

Author keywords

Carbamazepine; Complex partial seizures; Gabapentine; Kindling; Lamotrigine; Phenytoin; PNU 151774E; Rat

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; SAFINAMIDE; UNCLASSIFIED DRUG;

AFTERDISCHARGE; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; INTRAPERITONEAL DRUG ADMINISTRATION; KINDLING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETIC ACIDS; ALANINE; AMINES; AMYGDALA; ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; BENZYLAMINES; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY, COMPLEX PARTIAL; GAMMA-AMINOBUTYRIC ACID; KINDLING, NEUROLOGIC; MALE; PHENYTOIN; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX; TRIAZINES;

EID: 0342712672     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb02035.x     Document Type: Article

References (30)

1. Shorvon SD. Epidemiology, classification, natural history, and genetics of epilepsy. Lancet 1990;336:93-6.
2. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334:168-75.
3. Engel JJ. Surgery for seizures. N Engl J Med 1996;334:647-52.
4. Mattson RH. Drug treatment of uncontrolled seizures. Epilepsy Res 1992;(suppl 5):29-35.
5. Gastaut H, Gastaut JL, Goncalves E, Silva GE, Fernandez Sanchez GR. Relative frequency of different types of epilepsy: a study employing the classification of the International League Against Epilepsy. Epilepsia 1975;16:457-61.
6. Mattson RH. Drug treatment of partial epilepsy. Adv Neurol 1992; 57:643-50.
7. Pevarello P, Bonsignori A, Dostert P, et al. Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives. J Med Chem 1998;41:579-90.
8. Fariello RG, McArthur RA, Bonsignori A, et al. Preclinical evaluation of PNU-151774E as a novel anticonvulsant. J Pharmacol Exp Ther 1998;285:397-403.
9. Salvati P, Algate A, Beard D, et al. Anticonvulsant profile of FCE 26743, a novel 2-aminopropionamide derivative. Poster presented at the Society for Neuroscience, 26th Annual Meeting, 1996, Washington, D.C.
10. Salvati P, Maj R, Caccia C. Biochemistry and electrophysiology of PNU-151774E, a novel and broad spectrum anticonvulsant. J Pharmacol Exp Ther 1999;288:1151-9.
11. Strolin Benedetti MS, Marrari P, Colombo M, et al. The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats. J Pharm Pharmacol 1994;46:814-9.
12. Ben-Ari Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 1985;14:375-403.
13. McNamara JO, Byrne MC, Dasheiff RM, Fitz JG. The kindling model of epilepsy: a review. Prog Neurobiol 1980;15:139-59.
14. Goddard GV. Development of epileptic seizures through brain stimulation at low intensity. Nature 1967;214:1020-1.
15. Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969;25:295-330.
16. Loscher W, Jacket R, Czuczwar SJ. Is amygdala kindling in rats a model for drug-resistant partial epilepsy? Exp Neurol 1986;93: 211-26.
17. Loscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 1988;2:145-81.
18. McNamara JO. Development of new pharmacological agents for epilepsy: lessons from the kindling model. Epilepsia 1989;30 (suppl 1):S13-8.
19. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972;32:281-94.
20. Maj R, Fariello RG, Ukmar G, et al., PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat. Eur J Pharmacol 1998;359:27-32.
21. Girgis M. Commentary kindling as a model for limbic epilepsy. Neuroscience 1981;6:1695-706.
22. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313:145-51.
23. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46:152-76.
24. McLean MJ. Clinical studies of gabapentin. Drugs Today 1995; 31:621-8.
25. Burdette DE, Sackellares JC. Felbamate pharmacology and use in epilepsy. Clin Neuropharmacol 1994;17:389-402.
26. O'Donnell RA, Miller AA. The effect of lamotrigine upon development of cortical kindled seizures in the rat. Neuropharmacology 1991;30:253-8.
27. Radulovic LL, Taylor CP, Walker RM. The preclinical pharmacology, pharmacokinetics and toxicology of gabapentin. Drugs Today 1995;31:597-611.
28. Thompson PJ, Trimble MR. Anticonvulsant serum levels: relationship to impairments of cognitive functioning. J Neurol Neurosurg Psychiatry 1983;46:227-33.
29. Bouman WP, Pinner G, Johnson H. Cognitive impairment associated with lamotrigine. Br J Psychiatry 1997;170:388-9.
30. Dodrill CB. Diphenylhydantoin serum levels, toxicity, and neuropsychological performance in patients with epilepsy. Epilepsia 1975;16:593-600.